Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998

Clinical Oncology

Volumn 16, Issue 4, 2004, Pages 261-268

  Livi, L ^a   Andreopoulou, E ^b   Shah, N ^c   Paiar, F ^a   Blake, P ^b   Judson, I ^b   Harmer, Clive ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Prognosis; Radiotherapy; Uterine sarcomas

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIUM SARCOMA; FEMALE; FOLLOW UP; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; POPULATION RESEARCH; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR CLASSIFICATION; UNITED KINGDOM; UTERUS SARCOMA;

EID: 2542585355     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2004.01.010     Document Type: Article

References (35)

1. Olah KS, Dunn JA, Gee H. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 1991;27:1095-1099.
2. Marchese MJ, Liskow AS, Crum CP, et al. Uterine sarcomas: a clinicopathologic study, 1965-1981. Gynecol Oncol 1984; 18:299-312.
3. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
4. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
5. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 334:187-202.
6. Sobin LH, Wittekind C. TNM Classification of malignant tumours, 6th edn. New York: Wiley-Liss, 2002.
7. Piver MS, Lele SB, Marchetti DL, et al. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol 1998;38:233-239.
8. Gadducci A, Fabrini MG, Facchini V, et al. Surgery and radiotherapy in the treatment of early stage uterine sarcomas. Eur J Gynaecol Oncol 1989;10:276-280.
9. Moskovic E, MacSweeney E, Law M, et al. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993;66:1009-1015.
10. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 2001;27:282-285.
11. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-2130.
12. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998; 68:1-13.
13. Pecorelli S. EORTC Gynecological cancer groups: adjuvant pelvic radiotherapy versus observation alone in patients with completely resected stage I or II high grade uterine sarcoma.
14. Knocke T, Kucera H, Dorfler D, et al. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998;83:1972-1979.
15. Bai P, Sun J, Chao H. A clinical analysis of 153 uterine sarcomas. Zhonghua Fu Chan Ke Za Zhi 1997;32:163-167.
16. Coquard R, Romestaing P, Ardiet JM, et al. Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy. Bull Cancer 1997;84:625-629.
17. Anonymous. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350: 1647-1654.
18. Nordal RR, Kristensen GB, Kaern J, et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1995;34:797-802.
19. Nordal RR, Kristensen GB, Stenwig AE, et al. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 1997; 67:316-321.
20. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997; 33:907-911.
21. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol 1992;99:590-594.
22. Bodner-Adler B, Bodner K, Obermair A, et al. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res 2001;21:3069-3074.
23. Watanabe Y, Roy JN, Harrington PJ, et al. Three-dimensional lookup tables for Henschke applicator cervix treatment by HDR 192IR remote afterloading. Int J Radiat Oncol Biol Phys 1998; 41:1201-1207.
24. Verellen D, Deneve W, Van den Heuvel F, et al. On the determination of the effective transmission factor for stainless steel ovoid shielding segments and estimation of their shielding efficacy for the clinical situation. Med Phys 1994;21:1677-1684.
25. Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47-52.
26. Hoffmann W, Schmandt S, Kortmann RD, et al. Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases. Gynecol Obstet Invest 1996;42:49-57.
27. Riddle PJ, Echeta CB, Manek S, et al. Retrospective study of management of uterine sarcomas at Oxford 1990-1998: role of adjuvant treatment. Clin Oncol 2002;14:54-61.
28. Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987;5:618-621.
29. Kushner DM, Webster KD, Belinson JL, et al. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol 2000;78:221-227.
30. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985;3:1240-1245.
31. Tore G, Topuz E, Bilge N, et al. The role of adjuvant chemotherapy in the treatment of uterine sarcoma patients. Eur J Gynaecol Oncol 1990;11:307-312.
32. Szlosarek PW, Lofts FJ, Pettengell R, et al. Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anticancer Drugs 2000;11:275-278.
33. Gadducci A, Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol 2001; 22:352-357.
34. Hensley ML, Maki R, Venkatraman E, et al. Gemcitibine and docitaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
35. Wang CJ, Leung SW, Chen HC, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys 1998;40:85-91.